Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Hims & Hers Health Inc’s stock clocked out at $32.47, down -1.73% from its previous closing price of $33.04. In other words, the price has decreased by -$1.73 from its previous closing price. On the day, 14.03 million shares were traded. HIMS stock price reached its highest trading level at $32.9387 during the session, while it also had its lowest trading level at $32.065.
Ratios:
To gain a deeper understanding of HIMS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 63.67. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $48.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 22 ’25 when Okupe Oluyemi sold 23,090 shares for $35.72 per share. The transaction valued at 824,710 led to the insider holds 94,333 shares of the business.
Oluyemi Okupe bought 32,160 shares of HIMS for $1,127,208 on Dec 22 ’25. On Dec 17 ’25, another insider, Chi Michael, who serves as the Chief Operating Officer of the company, sold 13,750 shares for $36.71 each. As a result, the insider received 504,762 and left with 305,161 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 7391747584 and an Enterprise Value of 7880026112. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 60.03, and their Forward P/E ratio for the next fiscal year is 54.27. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.34 while its Price-to-Book (P/B) ratio in mrq is 12.71. Its current Enterprise Value per Revenue stands at 3.564 whereas that against EBITDA is 46.765.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.36, which has changed by 0.21930158 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $23.97. The 50-Day Moving Average of the stock is -17.16%, while the 200-Day Moving Average is calculated to be -29.06%.
Shares Statistics:
It appears that HIMS traded 22.79M shares on average per day over the past three months and 10881450 shares per day over the past ten days. A total of 219.12M shares are outstanding, with a floating share count of 206.52M. Insiders hold about 9.28% of the company’s shares, while institutions hold 89.50% stake in the company. Shares short for HIMS as of 1765756800 were 64816789 with a Short Ratio of 2.84, compared to 1763078400 on 67552266. Therefore, it implies a Short% of Shares Outstanding of 64816789 and a Short% of Float of 35.22.
Earnings Estimates
The firm’s stock currently is rated by 11.0 analysts. The consensus estimate for the next quarter is $0.15, with high estimates of $0.3 and low estimates of $0.1.
Analysts are recommending an EPS of between $0.58 and $0.38 for the fiscal current year, implying an average EPS of $0.48. EPS for the following year is $0.66, with 11.0 analysts recommending between $1.37 and $0.33.
Revenue Estimates
In. The current quarter, 12 analysts expect revenue to total $617.48M. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 12 analysts are estimating revenue of $658.67M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $630.7M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.77B in the next fiscal year. The high estimate is $2.94B and the low estimate is $2.52B.
